Skip to Main Content
Table 2

Antitumor activity and toxicity of different schedules of topotecan administered intravenously in mice

Schedule of administrationaLife span (days)Increased life span (%)Maximum body weight loss (%)
Controls 59 ± 2.1   
12.5 mg/kg × 1 60.1 ± 14.6 
2.5 mg/kg (d × 5)b 82.3 ± 3.4 40 7.3 
1.25 mg/kg (d × 5)2b 77.8 ± 8 32 2.4 
0.625 mg/kg (d × 5)4b 96 ± 6 63 
Schedule of administrationaLife span (days)Increased life span (%)Maximum body weight loss (%)
Controls 59 ± 2.1   
12.5 mg/kg × 1 60.1 ± 14.6 
2.5 mg/kg (d × 5)b 82.3 ± 3.4 40 7.3 
1.25 mg/kg (d × 5)2b 77.8 ± 8 32 2.4 
0.625 mg/kg (d × 5)4b 96 ± 6 63 
a

Topotecan treatment began 3 days after tumor implantation.

b

Topotecan was administered i.v. 5 days/week, for 1, 2, or 4 consecutive weeks.

Close Modal

or Create an Account

Close Modal
Close Modal